Battered Gemphire shares soar on new triglyceride data, but there’s a lot left to prove
Less than a year after Gemphire shares $GEMP were doused by poor LDL numbers for its lead drug gemcabene, investors rallied to the cause with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
